|
| Press Releases |
|
 |
|
| Tuesday, September 14, 2021 |
|
|
Eisai to Join The Global Environmental Initiative "RE100" |
| Eisai Co., Ltd. announced today that it has joined "RE100", the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity. more info >> |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021 |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its oncology products and pipeline will be given at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, from September 16 to 21, 2021, including its in-house discovered lenvatinib mesylate and eribulin mesylate. more info >> |
|
| Monday, September 13, 2021 |
|
|
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients" |
| AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. announced today that, on September 13, 2021, the companies launched "Humira Support Tool Ordering Service for Patients" an initiative intended to improve patients' adherence to Humira therapy. more info >> |
|
| Tuesday, August 31, 2021 |
|
|
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries |
| Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand. more info >> |
|
| Monday, August 16, 2021 |
|
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide), in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
| Thursday, August 12, 2021 |
|
|
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC) |
| Eisai and Merck & Co., Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
| Thursday, August 5, 2021 |
|
|
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards |
| Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo). more info >> |
|
| Monday, August 2, 2021 |
|
|
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures |
| Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two additional approvals as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older" in China from the National Medical Products Administration. more info >> |
|
| Friday, July 30, 2021 |
|
|
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401) |
| Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) -- granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021. more info >> |
|
|
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021 |
| Biogen and Eisai Co., Ltd. today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer's disease called ICARE AD-US, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Michael Owen Becomes the New Face of GK8: Fastest Growing iGaming Brand 
Aug 3, 2025 13:00 HKT/SGT
|
|
|
Risetcar's driverless taxis are performing well in the US, with Jakarta operations set to launch soon
Aug 2, 2025 21:30 HKT/SGT
|
|
|
Kuvi.ai Launches Private Beta of Agentic Finance OS with Seed Round Led by Moon Pursuit Capital
Aug 2, 2025 11:30 HKT/SGT
|
|
|
Rust Mobile Revealed With Official Trailer, First Hands-on Demo Set for Gamescom 2025
Aug 2, 2025 00:30 HKT/SGT
|
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Aug 2, 2025 00:02 HKT/SGT
|
|
|
TSE Group Launches Papua's First POME-to-Energy Plant
Aug 1, 2025 23:00 HKT/SGT
|
|
|
Concord New Energy (0182.HK) Released 2025 Interim Results
Aug 1, 2025 21:49 HKT/SGT
|
|
|
Queensland's Stralis lands clean aviation breakthrough in Japan, announced at Expo 2025 Osaka
Aug 1, 2025 20:00 JST
|
|
|
Queensland leads global education charge at Expo 2025 Osaka
Aug 1, 2025 20:00 JST
|
|
|
Hitachi completes capital reorganization of air conditioning joint venture accelerating the deployment of green cooling solutions through "One Hitachi"
Aug 1, 2025 19:00 JST
|
|
|
Naoris Protocol Stakes $120,000 Bounty To Break Cryptography Securing $470 Trillion Global Economy
Aug 1, 2025 16:50 HKT/SGT
|
|
|
Mitsubishi Motors and Security Bank launch Mitsubishi Motors Finance Philippines Inc.
Aug 1, 2025 17:00 JST
|
|
|
Honda Turkiye A.S. decided to establish Motorcycle Production Factory
Aug 1, 2025 16:45 JST
|
|
|
Global Property Expo | Singapore 2025 attracts 2,500 Buyers With Intent, 40+ Exhibitors, with Projects spanning 20 Countries
Aug 1, 2025 14:48 HKT/SGT
|
|
|
Honda Begins Joint Demonstration of Stationary Fuel Cell Power Station Designed to Utilize By-product Hydrogen and Repurposed Automotive Fuel Cells
Aug 1, 2025 11:20 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
